Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) in a research report report published on Wednesday, MarketBeat.com reports. The firm issued an overweight rating and a $67.00 price objective on the stock. ZNTL has been the topic of several other reports. SVB Leerink increased their price objective on […]
Related Keywords
Thomson Reuter , Anthonyy Sun , Zentalis Pharmaceuticals Inc , Fieldpoint Private Securities , Zentalis Pharmaceuticals Get Rating , Zentalis Pharmaceuticals , Advisors Inc , Wells Fargo Company , Advisor Group Holdings Inc , Analyst Recommendations For Zentalis Pharmaceuticals , Wells Fargo , Get Rating , Director Cam Gallagher , Private Securities , Forest Capital Management , Group Holdings , Nasdaq Zntl , Zntl , Medical , Initiated Coverage ,
comparemela.com © 2020. All Rights Reserved.